{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phosphate+Buffered+Saline&page=3", "query": { "intervention": "Phosphate Buffered Saline", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 170, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phosphate+Buffered+Saline&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phosphate+Buffered+Saline&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T23:57:48.554Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04896086", "title": "First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza", "Seasonal Influenza" ], "interventions": [ { "name": "VRC-GENADJ0110-AP-NV (Adjuplex)", "type": "DRUG" }, { "name": "Flucelvax", "type": "BIOLOGICAL" }, { "name": "VRC-FLUMOS0111-00-VP (FluMos-v1)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 63, "start_date": "2021-05-24", "completion_date": "2024-01-25", "has_results": true, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04896086" }, { "nct_id": "NCT02277197", "title": "Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck", "Squamous Cell Carcinoma of the Head and Neck", "Squamous Cell Carcinoma, Head And Neck" ], "interventions": [ { "name": "Ficlatuzumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James J Lee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-08", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 3, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277197" }, { "nct_id": "NCT03275389", "title": "A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "D-SUIV cH8/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH8/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH8/1N1", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Fluarix Quadrivalent", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 470, "start_date": "2017-09-08", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-05-07", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 5, "location_summary": "South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Austin", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275389" }, { "nct_id": "NCT03005418", "title": "Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Trauma", "Vascular System Injury" ], "interventions": [ { "name": "Acellular Tissue Engineered Vessel (ATEV)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Humacyte, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 72, "start_date": "2018-09-01", "completion_date": "2026-05-15", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 27, "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03005418" }, { "nct_id": "NCT02030301", "title": "Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Genital Herpes Simplex Type 2" ], "interventions": [ { "name": "VCL-HB01", "type": "BIOLOGICAL" }, { "name": "VCL-HM01", "type": "BIOLOGICAL" }, { "name": "PBS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 165, "start_date": "2013-12", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2019-02-27", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02030301" }, { "nct_id": "NCT05346302", "title": "Persistent Readiness Through Early Prediction Immunization Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Inflammatory Response" ], "interventions": [ { "name": "Pneumovax 23", "type": "DRUG" }, { "name": "Typhim VI", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Texas A&M University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 249, "start_date": "2022-02-08", "completion_date": "2022-12-21", "has_results": false, "last_update_posted_date": "2023-02-14", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 1, "location_summary": "College Station, Texas", "locations": [ { "city": "College Station", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05346302" }, { "nct_id": "NCT05177328", "title": "Targeted Investigation of Microbiome Elimination", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "S. hominis A 9 Product", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 21, "start_date": "2022-07-18", "completion_date": "2023-10-13", "has_results": true, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05177328" }, { "nct_id": "NCT01753830", "title": "Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Knee Osteoarthritis" ], "interventions": [ { "name": "Durolane", "type": "DEVICE" }, { "name": "PBS", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 75, "start_date": "2012-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2022-08-26", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 25, "location_summary": "Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01753830" }, { "nct_id": "NCT01032889", "title": "Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate or Severe Submental Fullness" ], "interventions": [ { "name": "Deoxycholic acid injection", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kythera Biopharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 129, "start_date": "2009-12", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-06-15", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Beverly Hills, California • San Francisco, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Naperville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01032889" }, { "nct_id": "NCT00333398", "title": "Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free", "type": "BIOLOGICAL" }, { "name": "CSL Trivalent Inactivated Influenza Vaccine with Thimerosal", "type": "BIOLOGICAL" }, { "name": "Placebo with Thimerosal", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 1359, "start_date": "2006-06", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2010-08-27", "last_synced_at": "2026-10-10T23:57:48.554Z", "location_count": 10, "location_summary": "Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333398" } ] }